[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561920":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":35,"centralContacts":39,"locations":49,"responsibleParty":68,"collaborators":34,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":34,"eligibilityCriteria":77,"healthyVolunteers":74,"sex":78,"minAge":79,"maxAge":34,"enrollmentInfo":80,"targetDuration":34,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":51,"whyStopped":34,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"University of Arizona","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A: 4-aminopyridine","ACTIVE_COMPARATOR","Dalfampridine (generic) 10 mg capsule PO every 12 hours",[13],"Drug: Drug: 4-Aminopyridine",{"label":15,"type":16,"description":17,"interventionNames":18},"Group B: Placebo","PLACEBO_COMPARATOR","Placebo - 1 capsule PO every 12 hours",[19],"Other: Placebo",[21,30],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Drug: 4-Aminopyridine","Active study drug",[9],[27,28,29],"4AP","4-AP","Dalfampridine",{"type":6,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"Placebo","Placebo comparator",[15],null,[36],{"name":37,"affiliation":5,"role":38},"John Elfar, MD","PRINCIPAL_INVESTIGATOR",[40,45],{"name":41,"role":42,"phone":43,"phoneExt":34,"email":44},"Carly J Deal, MPH","CONTACT","520-626-1588","carlyjdeal@arizona.edu",{"name":46,"role":42,"phone":47,"phoneExt":34,"email":48},"Veronica Rangel, BS","5206264024","vrangel@arizona.edu",[50],{"facility":5,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"RECRUITING","Tucson","Arizona","85724","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-110.92648,32.22174,{"lat":61,"lon":60},[64,66],{"name":65,"role":42,"phone":43,"phoneExt":34,"email":44},"Carly J Deal",{"name":46,"role":42,"phone":67,"phoneExt":34,"email":48},"5206164024",{"type":69,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":34,"oldOrganization":34},"SPONSOR_INVESTIGATOR","John Elfar","Tenured Professor, Chairman, Department of Orthopaedic Surgery","100561920","phase-2-4-aminopyridine-to-treat-skin-burns-100561920",false,"NCT06596434","4-Aminopyridine to Treat Skin Burns","Inclusion Criteria:\n\n* Injured (burned) adults with a maximum severity of second-degree burns.\n* Burns involving at least 6cm2 of skin area\n* Acute burns within 7 days of injury\n* Cognitive ability to evaluate burn healing, report sensory and motor deficit during examination.\n* Adults aged 18-80\n* Ability to give written informed consent.\n* Capable of safely coming in for follow up visits on all scheduled appointments.\n\nExclusion Criteria:\n\n* History of multiple sclerosis, stroke or any other diagnosed neurological disorder\n* History of hypersensitivity to AMPYRA® or 4-aminopyridine\n* Current use of aminopyridine medications, including other compounded 4-AP\n* Suspected renal impairment based on the Choyke questionnaire.\n* History of difficult compliance with timely follow up\n* Patients outside the age range\n* Unable to provide informed consent.\n* Patients with a known history of a seizure disorder (4-AP overdose can, in selected cases, result in limited seizure activity).\n* Patients with a concomitant traumatic brain injury.\n* Patients unable to communicate.\n* Patients unwilling to complete the study requirements.\n* Patients currently taking organic cat-ion transporter 2 (OCT2) inhibitors, e.g. Cimetidine.\n* Pregnancy, breastfeeding or incarcerated individuals.\n* Non-English speaking\n* Patients unable or unwilling to take calibrated (with gauge) photographs of their wounds","ALL","18 Years",{"count":81,"type":82},200,"ESTIMATED","INTERVENTIONAL",[85],"PHASE2","Many patients suffer from traumatic burns and current treatments do not increase the regenerative potential of either skin grafts or the remaining uninjured skin. There is a need to develop treatments to accelerate and improve healing of burn injuries. More research is needed to evaluate the role of 4-AP, a promising new agent with an excellent safety profile, on wound and burn healing. The investigational treatment will be used to test the hypothesis that 4-AP accelerates burn healing in traumatically burned patients.",[88,89,90],"Burns","Second Degree Burn","Wounds and Injuries",[92,28,88,93,94],"4-aminopyridine","Second degree burn","Wounds","2026-03-04",{"date":97,"type":98},"2026-03-05","ACTUAL",{"date":100,"type":98},"2026-01-01",{"date":102,"type":82},"2028-09",{"name":70,"class":6},1]